Beranda › Limfoma Sel Mantel
Uji klinis Limfoma Sel Mantel yang merekrut di AS
70 studi untuk Limfoma Sel Mantel merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Baldwin Park, CA15 studi
- Houston, TX15 studi
- Durham, NC13 studi
- New York City, NY12 studi
- Milwaukee, WI12 studi
- Seattle, WA12 studi
- Boston, MA11 studi
- Columbus, OH11 studi
- Nashville, TN11 studi
- Chicago, IL10 studi
- Portland, OR9 studi
- Rochester, MN9 studi
- St. Louis, MO8 studi
- Atlanta, GA8 studi
- Denver, CO8 studi
- Mountain View, CA7 studi
- Cleveland, OH7 studi
- Los Angeles, CA7 studi
- Dallas, TX6 studi
- Salt Lake City, UT6 studi
- Miami, FL6 studi
- Jacksonville, FL6 studi
- Ann Arbor, MI6 studi
- Buffalo, NY5 studi
- Kansas City, MO5 studi
- Charlotte, NC5 studi
- Tampa, FL5 studi
- Baltimore, MD5 studi
- New Haven, CT5 studi
- Washington, DC5 studi
- Edison, NJ5 studi
- Philadelphia, PA5 studi
- San Diego, CA5 studi
- Providence, RI4 studi
- Minneapolis, MN4 studi
- Pittsburgh, PA4 studi
- Charlottesville, VA4 studi
- Queens, NY4 studi
- Omaha, NE4 studi
- Cedar Rapids, IA4 studi
Berdasarkan negara bagian
- Alabama4 studi
- Arizona6 studi
- California29 studi
- Colorado10 studi
- Connecticut6 studi
- Delaware3 studi
- Florida16 studi
- Georgia9 studi
- Illinois10 studi
- Indiana4 studi
- Iowa5 studi
- Kansas7 studi
- Kentucky4 studi
- Louisiana3 studi
- Maryland9 studi
- Massachusetts13 studi
- Michigan8 studi
- Minnesota14 studi
- Missouri8 studi
- Nebraska4 studi
- New Jersey8 studi
- New York16 studi
- North Carolina17 studi
- Ohio16 studi
- Oregon9 studi
- Pennsylvania9 studi
- Rhode Island4 studi
- Tennessee12 studi
- Texas19 studi
- Utah6 studi
- Virginia7 studi
- Washington14 studi
- Wisconsin13 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05976763Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05724121Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07763210Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07285044A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06697184Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06553872Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06029309Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06564038A Study of ARC-02 in B-cell NHL
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Menerima pesertaFase 1
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Menerima pesertaFase 1
Usia 18 hingga 81 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05990465Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07121946Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.